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Abstract
Background: The inflammatory disease periodontitis results in tooth loss and can even lead to diseases of the
whole body if not treated. Gingival crevicular fluid (GCF) reflects the condition of the gingiva and contains proteins
transuded from serum or cells at inflamed sites. In this study, we aimed to discover potential protein biomarkers
for periodontitis in GCF proteome using LC-MS/MS.
Results: We identified 305 proteins from GCF of healthy individuals and periodontitis patients collected using a
sterile gel loading tip by ESI-MS/MS coupled to nano-LC. Among these proteins, about 45 proteins were
differentially expressed in the GCF proteome of moderate periodontitis patients when compared to the healthy
individuals. We first identified azurocidin in the GCF, but not the saliva, as an upregulated protein in the
periodontitis patients and verified its increased expression during periodontitis by ELISA using the GCF of the
classified periodontitis patients compared to the healthy individuals. In addition, we found that azurocidin inhibited
the differentiation of bone marrow-derived macrophages to osteoclasts.
Conclusions: Our results show that GCF collection using a gel loading tip and subsequent LC-MS/MS analysis
following 1D-PAGE proteomic separation are effective for the analysis of the GCF proteome. Our current results
also suggest that azurocidin could be a potential biomarker candidate for the early detection of inflammatory
periodontal destruction by gingivitis and some chronic periodontitis. Our data also suggest that azurocidin may
have an inhibitory role in osteoclast differentiation and, thus, a protective role in alveolar bone loss during the
early stages of periodontitis.
Background
Periodontal diseases are a type of inflammatory disease
that affect the periodontium surrounding and support-
ing the teeth and are caused by microorganisms that
adhere to and grow on the surfaces of teeth. Most cases
of destructive periodontitis are composed of aggressive
and chronic periodontitis [1]. Half of the adults in the
U.S. suffer from chronic periodontitis, which is the most
general form of destructive periodontitis, and about 10%
of the population is at a high risk for severe periodonti-
tis [2]. It has been suggested that chronic periodontitis
can lead to bone loss and tooth mortality, which might
lead to further systemic diseases, e.g., cardiovascular dis-
ease and stroke [3,4].
A diagnosis of periodontitis is established by tradition-
ally used indices, e.g., bleeding upon probing and prob-
ing depth, which indicate the loss of periodontal tissue
attachment to the teeth [5,6]. Additionally, radiography
visualizes the loss of periodontal tissue, which supports
the diagnosis by determining the amount of bone loss
around the teeth [7]. However, these methods are only
useful when attachment loss has occurred to some
degree. For chair-side and single visits, more reliable
biomarkers for periodontitis are needed to provide con-
stant classification and customized treatment and for
monitoring periodontal diseases [8,9].
Gingival crevicular fluid (GCF) is bodily fluid that
reflects the condition of the periodontium [10]. GCF con-
tains various components that originate by transudation
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from the interaction between the bacterial biofilm and
the cells of periodontal tissues [11,12]. Additionally,
despite a large variation, the amount of GCF tends to
increase with the severity of gingival inflammation [13].
In addition to these characterizations, the simple and
noninvasive collection of GCF is required for the discov-
ery of periodontitis biomarkers. However, GCF collection
using filter paper strips and microcapillary tubes, two
generally used methods, have drawbacks such as nonspe-
cific binding of the analyte to paper fibers and the loss of
the collected sample, respectively [10].
In previous decades, proteomic analysis has been suc-
cessfully used for various purposes, such as the identifi-
cation of binding partner proteins to certain factors and
novel proteins derived under specific circumstances. In
particular, proteomic technology has become an impor-
tant tool for the discovery of protein/peptide biomar-
kers. Proteomic analysis of bodily fluids, e.g., blood,
urine, and GCF, is widely used for biomarker discovery
because of its easy accessibility for analysis and diagno-
sis [14].
In this study, we isolated GCF from periodontitis
patients and healthy individuals using a gel loading tip.
In an effort to discover potential protein biomarkers for
periodontitis in GCF, protein samples from the GCF
were used for the analysis of the GCF proteome using
LC-MS/MS.
Methods
Human GCF samples
GCF samples were collected from periodontitis patients
and healthy individuals for the identification of period-
ontitis biomarkers at the Department of Periodontology,
School of Dentistry, Kyungpook National University.
The standard protocol was approved by the IRB of
Kyungpook National University Hospital (IRB NO.
74005 - 830). Informed consent was obtained from all
donors.
Clinical parameters and the establishment of a standard
protocol for GCF collection
To stratify the chronic gingivitis and chronic periodonti-
tis patients, the clinical periodontal parameters from
average 6 sites per individual were assessed at the initial
examination for mean probing depth (PD), clinical
attachment loss (CAL), bleeding upon probing (BOP),
and the gingival index (GI) (Table 1) [15]. According to
the criteria and complications, we divided the samples
into normal (N), chronic gingivitis (GV), moderate peri-
odontitis (MP), and severe periodontitis (SP) and col-
lected GCF with a sterile gel loading tip (DASLAB,
Spain). Each individual sample was collected from the
sites of gingival sulcus with same classification of
periodontitis according to our criteria. Because of the
small volume of collected GCF (about 0.5 to 2 μlp e r
patient), all of the collected samples were directly
diluted into 20 μl of 0.9% NaCl solution for the conveni-
ence of sample preparation. Diluted samples were
centrifuged at 13,000 g (4°C) for 15 min, and the super-
natants were transferred to new tubes to remove con-
taminants such as tissue debris. The transferred samples
were used for protein quantification and stored at -70°C
until further assay (Figure 1A). Among the 869 GCF
samples (161 normal, 229 gingivitis, 296 moderate peri-
odontitis, and 183 severe periodontitis) collected from
July 2009 to Aug. 2010, we used GCF samples without
complications such as diabetes, arteriosclerosis, hepatitis,
AIDS, hypertension, or pregnancy for LC-MS/MS analy-
sis, western blotting, and ELISA.
Collection of gingival tissue
Gingival tissue samples were obtained from patients
undergoing periodontal surgery at the Department of
Periodontology, School of Dentistry, Kyungpook National
University. The standard protocol was approved by the
IRB of Kyungpook National University Hospital (IRB
NO. 74005 - 830). Informed consent was obtained from
all donors. Gingival tissues were classified as normal (N),
gingivitis (GV), moderate periodontitis (MP), or severe
periodontitis (SP) according to criteria such as the gingi-
val index considered immune reaction, probing depth,
clinical attached loss, and bone loss on radiograph (Table
1). For western blotting, gingival tissues were isolated
from 2 healthy individuals (N), 3 with chronic gingivitis
(GV), 3 with moderate periodontitis (MP), and 3 with
severe periodontitis (SP).
LC-ESI-MS/MS analysis following in-gel digestion
We selected GCF samples collected from 11 normal (N)
and 12 moderate periodontitis (MP) patients without sys-
temic complications (Additional files 1) for analysis of
the GCF proteomes using LC-MS/MS. Twenty micro-
grams of pooled samples was separated by 1D gel electro-
phoresis. Gels were stained with Bio-Safe Coomassie
S t a i ns o l u t i o n( B i o - R a d ,H e r c u l e s ,C A )f o r1ha n d
destained by incubation in ddH2O. In-gel tryptic diges-
tion was performed as previously described [16]. Briefly,
protein bands were excised from Coomassie-stained gels
and destained. Disulfide bonds were reduced by treat-
ment with 5 mM Dithiothreitol (DTT)/25 mM ammo-
nium bicarbonate (Sigma-Aldrich, St. Louis, MO) at 60°C
for 30 min, followed by alkylation with 55 mM iodoaceta-
mide (Sigma-Aldrich, St. Louis, MO) at RT for 30 min.
The gel pieces were dehydrated in 100% acetonitrile
(ACN) (Sigma-Aldrich, St. Louis, MO) and dried. They
were then subsequently rehydrated in 10 μlo f2 5m M
ammonium bicarbonate buffer containing 20 μg/ml
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Germany) and incubated overnight at 37°C. The tryptic
peptide mixture was eluted from the gel with 0.1% formic
acid (Fluka, Switzerland).
LC-MS/MS analysis was performed using a Thermo
Finnigan ProteomeX workstation LTQ linear ion trap
MS/MS (Thermo Electron, San Jose, CA, USA) equipped
with NSI sources (San Jose, CA) as previously reported
[ 1 7 , 1 8 ] .B r i e f l y ,1 2μl of peptide sample from the in-gel
digestion was injected and loaded onto a peptide trap
cartridge (Agilent, Palo Alto, CA). Trapped peptides were
eluted onto a 10-cm reversed-phase PicoFrit column
packed in-house with 5 μm ,3 0 0Åp o r es i z eC 1 8a n d
then separated by gradient elution. The mobile phases
consisted of H2O (A) and ACN (B), and both phases con-
tained 0.1% (v/v) formic acid. The gradient started at 2%
B, reached 60% B in 50 min, 80% B in the next 5 min,
and 100% A in the final 15 min. Data-dependent acquisi-
tion (m/z 400-1800) was enabled. Each survey MS scan
was followed by five MS/MS scans within 30 sec with the
dynamic exclusion option on. The dynamic exclusion
option is a tool for the exclusion of basal peaks to
Table 1 Criteria for the classification of collected GCF
NG V M P S P
GI 0 1 2 3
Normal
gingiva
mild inflammation, slight
change in color and slight
edema, no BOP
moderate inflammation,
redness, edema, glazing,
BOP
severe inflammation, marked redness and
edema, ulceration, tendency toward
spontaneous bleeding
PD 1 mm ≤ 3m m 3-7m m ≥ 7m m
CAL 0 0 < 5 mm ≥ 5m m
Evidence of bone
loss on
radiograph
-- + +
Figure 1 Schematic diagram of the experimental procedures and 1D SDS gel image after Coomassie staining. (A) GCF samples were
collected from healthy individuals and chronic gingivitis, moderate periodontitis and severe periodontitis patients using a gel loading tip. The
collected samples were diluted with 0.9% NaCl solution, and the GCF proteins were isolated. Analysis of the GCF proteome was performed using
LC-MS/MS. The proteins selected as candidate biomarkers of periodontitis were verified using western blotting and ELISA. (B) Pooled samples
from 2 sets were separated by 1D SDS-PAGE and stained with Coomassie Brilliant Blue for the visualization of proteins. The stained proteins were
excised in 15 pieces for in-gel trypsin digestion. Peptides were isolated from four pooled samples, 2 normal and 2 chronic periodontitis, and
analyzed in duplicate by LC-MS/MS (Additional files 1). All subjects were non-smokers and had no other disease indications or other conditions,
e.g., diabetes, arteriosclerosis, hepatitis, AIDS, hypertension or pregnancy.
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noise in MS/MS peaks.
Data analysis
Tandem mass spectra were extracted and charge state
deconvoluted and deisotoped using Sorcerer 3.4 beta2
(Sorcerer software 3.10.4, Sorcerer Web interface 2.2.0
r334 and Trans-Proteomic Pipeline 2.9.5), as previously
reported [18]. All MS/MS samples were analyzed using
SEQUEST (Thermo Finnigan, San Jose, CA; version v.27,
rev. 11). SEQUEST was set to search the IPI Human 3.49
database (IPI ver. 3.49, 74,017 entries) assuming semiTryp-
sin as the digestion enzyme. SEQUEST search parameters
were set to a fragment ion mass tolerance of 1.0 Da and a
parent ion tolerance of 1.5 Da. Oxidation of methionine
and iodoacetamide modification of cysteine were specified
as fixed modifications. Scaffold (version Scaffold-
02_04_00, Proteome Software Inc., Portland, OR) calcu-
lates the quantitative value number by normalizing the
spectral counts across our Scaffold experiment. For
improved false-positive statistics, the decoy option was
selected during the data search process in the Sorcerer
program, which improves the quality of the results by
reducing the effects of noise. Comparative data analysis
using Scaffold was subsequently used to validate MS/MS-
based peptide and protein identifications. Protein identifi-
cations were accepted if they could be established at a
confidence level greater than 95.0% probability, as speci-
fied by the Peptide Prophet algorithm [19]. Protein prob-
abilities were assigned by the Protein Prophet algorithm
[20]. Proteins that contained similar peptides and that
could not be differentiated based on the MS/MS analysis
alone were grouped to satisfy the principles of parsimony.
The peptide false positive (FPR) rate was calculated using
the Scaffold software. For each charge state, incorrect
assignments were tabulated to calculate the FPRi =
[(#Assigned Incorrect at 95% probability)/(Total# Incor-
rect Assigned)]*100, with i being the charge state. The
assignment is considered correct if it is associated with a
protein that has a 95% probability, according to the Pro-
tein Prophet algorithm, and if a minimum of 2 peptides
are matched with the protein sequence, each with a 95%
probability, based on the Peptide Prophet algorithm. After
identifying the proteins, each dataset was used for a sub-
tractive analysis by quantitative value, which normalizes
the spectral counts in the Scaffold program.
Western Blot
Western blots were performed as previously reported
[21]. Briefly, 5 μg of gingival tissue was separated by 15%
SDS-PAGE (Elpis-Biotech, Korea) for azurocidin. After
electrophoresis, the proteins were transferred to PVDF
membrane (Roche, USA), which was incubated with anti-
human azurocidin antibody (Santa Cruz, CA) (1:1000)
and b-actin antibody (Abcam, Cambridge, MA) (1:2000),
followed by an anti-rabbit IgG antibody (1:2000) for azur-
ocidin and an anti-mouse IgG antibody (1:2000) for
b-actin.
ELISA
For the verification of azurocidin expression in GCF, sam-
ples were selected from 31 N, 36 gingivitis (GV), 59 MP,
and 30 severe periodontitis (SP) patients (Additional files
2). Selected samples were collected from non-smokers and
subjects having no complications (Additional files 2). The
ELISA (Cusabio, China) for azurocidin was performed fol-
lowing the manufacturer’s instructions. Briefly, samples
were added in a well and incubated for 2 h (37°C). The
liquid from each well was removed, and 100 μl of biotin-
antibody working solution was then added to each well for
1 h (37°C). The mixture was removed and washed with
the provided buffer (350 μl) using a multi-channel pipette.
After washing, HRP-avidin working solution was added to
each well and incubated for 1 h (37°C). After washing,
TMB substrate was added and incubated for 30 min
(37°C), and the reaction was stopped by adding 50 μlo f
Stop Solution to each well. The optical density of each
well was determined using a microplate reader set to
450 nm.
Osteoclast differentiation and TRAP staining
Bone marrow cells were isolated from the tibiae and
femora of 5-week-old BALB/c mice and cultured with a-
MEM containing 10% FBS in a humidified incubator (5%
CO2) at 37°C. After 24 h, non-adherent cells were centri-
fuged to obtain bone marrow-derived macrophage (BMM)
cells and incubated for use as adherent BMM for 3 days in
the presence of 20 ng/ml macrophage colony stimulating
factor (M-CSF) (Peprotech, USA). For the osteoclastogen-
esis experiments, BMM cells were cultured in the presence
of 20 ng/ml RANKL (R&D, USA) and 20 ng/ml M-CSF
with azurocidin (R&D, USA) at the indicated concentra-
tion. TRAP staining was performed according to the man-
ufacturer’s instructions (Sigma, USA) [22].
Statistical analysis
The data are presented as the means ± SE. The statistical
significance of the results was assessed using one-way
ANOVA, followed by Student’s t-test for unpaired sam-
ples. All p-values were derived from two-tailed statistical
tests, and a p-value < 0.05 wasr e g a r d e da ss t a t i s t i c a l l y
significant.
Results
General strategy and GCF protein visulalization by
Coomassie staining
To analyze the GCF proteomes by LC-MS/MS, we
selected 11 normal (N) and 12 moderate periodontitis
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tional files 1). For a representative group of periodonti-
tis, MP samples were selected for LC-MS/MS analysis.
Proteins in the pooled samples were separated by SDS-
PAGE. The patterns of SDS-PAGE-separated proteins
were visualized by Coomassie staining (Figure 1B). In
the region near 37 kDa (8
th band of the first pool and
7
th band of the second pool), a protein band was stained
more intensely in MP compared to N.
Analysis of the GCF proteome by LC-MS/MS
Proteins from 4 different pooled GCF samples were
identified by the duplicate LC-MS/MS analysis of each
(total of 8 analyses). By searching the human IPI data-
bases with a protein identification criteria of at least 2
peptides, a total of 305 proteins were identified from the
combined analysis of both the N and MP samples
(Additional files 3). These data revealed that the reverse
peptide hit rate was 0.94 ± 0.1% of total peptide hits
using the decoy protein database. After normalization of
the spectral counts by total ion currents in the Scaffold
program, we calculated the average spectral counts of 4
analyses (duplicate analysis of two sets of experiments)
in each N and MP sample and then calculated the fold
ratio of MP vs. N (MP/N). The results revealed that 25
proteins demonstrated a 2-fold or higher ratio of aver-
age spectral counts in the MP samples (Table 2), and 20
proteins demonstrated a 2-fold or higher ratio of aver-
age spectral counts in the N samples (Table 3). Addi-
tionally, 45 proteins were classified based on biological
process, cellular component, and molecular function
using the UniProt database (Tables 2 and 3). By search-
ing the NCBI bacterial database, proteins from bacteria
known to cause periodontitis were also identified (Addi-
tional files 4).
Verification of azurocidin expression in GCF using ELISA
Among the proteins upregulated in periodontitis, azuro-
cidin was first selected to validate on a larger scale
because it is known to be secreted by neutrophils upon
inflammatory challenges and because it is an attractant
for monocyte infiltration into inflamed tissues [23,24].
Thus, azurocidin levels were measured by western blot-
ting and ELISA in the same samples used for LC-MS/
MS analysis (Figures 2A and 2B). Using an ELISA, azur-
ocidin was detected at an 8.8-fold higher level (10.6 pg/
ml in N and 92.5 pg/ml in MP) in the GCF of MP com-
pared to N. This dramatic increase may be due in part
to the higher sensitivity of ELISA. To avoid prejudice
against a small sample size, we performed an ELISA
a s s a yo fa z u r o c i d i nw i t h3 1N ,3 6g i n g i v i t i s( G V ) ,5 9
MP, and 30 severe periodontitis (SP) patients (Addi-
tional files 2), and the average levels of azurocidin in
each sample were 40.8 pg/ml, 136.6 pg/ml, 118.3 pg/ml,
and 85.3 pg/ml, respectively. With a 50 pg/ml cutoff,
the specificity is 74.2%, and the sensitivities are 66.7% in
GV, 76.3% in MP, and 60.0% in SP patients (Figure 2C,
Table 4). Additionally, azurocidin was also expressed at
a higher level in the gingival tissue of periodontitis
patients compared to healthy controls in the western
blotting assay (Figure 3). The detected sizes of azuroci-
din were approximately 27 kDa.
Effect of azurocidin on osteoclastogenesis
Severe periodontitis (SP) results in alveolar bone loss,
but not during the early stages of gingivitis. It has been
suggested that the regulatory factors of the immune
response can affect bone metabolism. Thus, we tested if
azurocidin could affect osteoclast differentiation. On day
3, TRAP staining was performed on azurocidin-treated
cultures. Osteoclast differentiation of BMM was
decreased by the azurocidin treatment (Figure 4), which
suggests that high levels of azurocidin at an early stage
m a yh a v eap r o t e c t i v er o l ei no s t e o c l a s t - a c t i v a t e da l v e o -
lar bone loss.
Discussion
In this study, using biologically-independent duplicate
experiments of an analytically duplicate LC-MS/MS ana-
lysis of the GCF from healthy individuals (N) and mod-
erate periodontitis (MP) patients, 305 proteins were
identified. Of these proteins, 45 were significantly up- or
downregulated in the GCF of MP patients. We collected
869 GCF samples from patients using a sterile gel load-
ing tip. Among these, we used GCF samples from
patients without complications such as diabetes, arterio-
sclerosis, hepatitis, AIDS, hypertension, or pregnancy for
LC-MS/MS analysis, western blotting, and ELISA. We
also validated that the azurocidin levels were elevated in
periodontitis patients by ELISA in about 150 samples
from stratified periodontitis samples and healthy
controls.
In our study, for GCF collection, we tried several
methods including paper and 26 gauge needles; how-
ever, we found that fine gel loading tips are a useful and
convenient method for the collection of as much GCF
as possible, which resulted in a shortened collection
time, a decreased loss of isolated volume and a reduc-
tion in the inconvenience/hostility of patients during
collection. We identified 305 proteins from the analysis
of the GCF proteome by GeLC-MS/MS and also first
detected azurocidin as a component of GCF (Additional
files 3). In addition, we showed that azurocidin has an
effect on the osteoclastogenesis of BMM. Proteins from
various bacteria were also identified by searching the
LC-MS/MS data against bacterial databases (Additional
files 4). However, we could not find significant differ-
ences in the bacterial proteomes of the GCF of N and
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Page 5 of 11Table 2 List of upregulated proteins in periodontitis GCF
# Identified Proteins Accession
Number
Biological process Cellular component Molecular function Molecular
Weight
NM P M P / N
fold
N/MP
fold
1 Catalase IPI00465436 hydrogen peroxide removal peroxisome mitogen
oxidoreductase
peroxidase
60 kDa 0.3 ± 0.4 3.0 ± 1.4 12.0 0.1
2 Adenylyl cyclase-associated
protein 1
IPI00008274 signal transduction cell membrane actin binding 52 kDa 0.5 ± 0.7 5.8 ± 6.0 11.5 0.1
3 Plastin-2 IPI00010471 T cell activation cell junction calcium ion binding 70 kDa 2.0 ± 0.7 15.0 ± 12.7 7.5 0.1
4 Alpha-actinin-1 IPI00013508 negative regulation of cellular
component
cytosol actin binding 103 kDa 1.5 ± 0.7 10.3 ± 13.1 6.8 0.1
5 Fibrinogen beta chain IPI00298497 platelet activation external side of
plasma membrane
cell surface binding 56 kDa 0.8 ± 0.4 4.8 ± 1.8 6.3 0.2
6 Hornerin IPI00398625 keratinization developmental
protein
282 kDa 1.0 ± 1.4 5.5 ± 4.2 5.5 0.2
7 Isoform 1 of Myosin-9 IPI00019502 cell shape cytosol motor protein 227 kDa 4.8 ± 3.9 23.5 ± 26.2 4.9 0.2
8 Myeloblastin IPI00027409 collagen degradation serine protease 28 kDa 2.3 ± 0.4 11.0 ± 2.8 4.9 0.2
9 Azurocidin IPI00022246 chemotaxis azurophil granule antimicrobial 27 kDa 2.0 ± 0.7 9.3 ± 1.8 4.6 0.2
10 Isoform 1 of Fibrinogen alpha
chain
IPI00021885 blood coagulation Secreted cell surface binding 95 kDa 0.8 ± 1.1 3.0 ± 2.1 4.0 0.3
11 Leukocyte elastase IPI00027769 inflammatory response secretory granule Serine protease 29 kDa 5.0 ± 4.2 16.0 ± 3.5 3.2 0.3
12 Matrix metalloproteinase-9 IPI00027509 collagen degradation extracellular matrix metalloprotease 78 kDa 3.8 ± 3.9 10.5 ± 12.7 2.8 0.4
13 HBD Hemoglobin subunit delta IPI00473011 oxygen transport hemoglobin complex oxygen binding 16 kDa 34.8 ±
7.4
94.8 ± 63.3 2.7 0.4
14 Coronin-1A IPI00010133 innate immune response cytoplasm actin filament
binding
51 kDa 5.0 ± 2.8 13.0 ± 13.4 2.6 0.4
15 Rho GDP-dissociation inhibitor 2 IPI00003817 immune response cytoplasm GTPase activator 23 kDa 5.0 ± 3.5 12.0 ± 4.9 2.4 0.4
16 Keratin, type II cytoskeletal 5 IPI00009867 assembly intermediate filament structural constituent 62 kDa 9.8 ±
11.0
21.8 ± 13.1 2.2 0.4
17 Macrophage-capping protein IPI00027341 assembly cytoplasm nucleus actin binding 39 kDa 1.8 ± 2.5 3.8 ± 1.8 2.1 0.5
18 HBA2 Hemoglobin subunit
alpha
IPI00410714 oxygen transport hemoglobin complex oxygen binding 15 kDa 49.8 ±
20.9
105.5 ±
66.5
2.1 0.5
19 Keratin, type II cytoskeletal 1 IPI00220327 fibrinolysis intermediate filament structural constituent 66 kDa 93.0 ±
79.2
196.5 ±
193.0
2.1 0.5
20 Annexin A3 IPI00024095 defense response to bacterium phagocytic vesicle calcium-dependent
phospholipid binding
36 kDa 4.5 ± 4.2 9.5 ± 0.7 2.1 0.5
21 Hemoglobin subunit beta IPI00654755 oxygen transport hemoglobin complex hypotensive agent 16 kDa 74.5 ±
7.1
155.8 ±
83.8
2.1 0.5
22 Keratin, type I cytoskeletal 9 IPI00019359 organization intermediate filament structural constituent 62 kDa 31.0 ±
22.6
64.8 ± 63.3 2.1 0.5
23 Keratin, type II cytoskeletal 2
epidermal
IPI00021304 keratinization intermediate filament structural constituent 66 kDa 32.3 ±
39.2
65.0 ± 72.1 2.0 0.5
24 Actin-related protein 2 IPI00005159 cellular component cytoplasm actin binding 45 kDa 0.8 ± 1.1 1.5 ± 0.7 2.0 0.5
25 S100-A9 IPI00027462 chemotaxis extracellular region calcium ion-binding
protein
13 kDa 44.8 ±
1.1
88.5 ± 1.4 2.0 0.5
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1Table 3 List of downregulated proteins in periodontitis GCF.
# Identified Proteins Accession
Number
Biological process Cellular
component
Molecular
function
Molecular
Weight
NM P M P / N
fold
N/MP
fold
1 Cystatin-A IPI00032325 keratinocyte cytoplasm cysteine-type
endopeptidase
inhibitor activity
11 kDa 4.5 ± 3.5 2.3 ± 1.1 0.5 2.0
2 Thymidine phosphorylase IPI00292858 chemotaxis glycosyltransferase 50 kDa 7.5 ± 2.8 3.8 ± 0.4 0.5 2.0
3 Cystatin-B IPI00021828 cytoplasm
nucleus
protease inhibitor 11 kDa 11.0 ± 5.7 5.3 ± 1.1 0.5 2.1
4 Cystatin-SN IPI00305477 secreted cysteine-type
endopeptidase
inhibitor activity
16 kDa 13.5 ± 0.7 6.3 ± 2.5 0.5 2.2
5 IGKV3D-15 Myosin-reactive immunoglobulin light chain
variable region
IPI00549330 13 kDa 6.3 ± 0.4 2.8 ± 0.4 0.4 2.3
6 Nucleoside diphosphate kinase B IPI00026260 transcription
regulation
cytoplasm
nucleus
kinase 17 kDa 6.0 ± 3.5 2.5 ± 1.4 0.4 2.4
7 14-3-3 protein epsilon IPI00000816 host-virus interaction cytoplasm histone
deacetylase
binding
29 kDa 9.0 ± 1.4 3.5 ± 3.5 0.4 2.6
8 Prolactin-inducible protein IPI00022974 secreted actin binding 17 kDa 15.0 ± 12.0 5.3 ± 6.0 0.4 2.9
9 alpha-2-glycoprotein 1, zinc IPI00166729 immune response secreted transmembrane
transporter activity
34 kDa 13.0 ± 2.8 4.5 ± 2.8 0.3 2.9
10 Polymeric immunoglobulin receptor IPI00004573 membrane
secreted
protein binding 83 kDa 76.0 ± 34.6 25.3 ±
31.5
0.3 3.0
11 Lipopolysaccharide-responsive and beige-like anchor
protein
IPI00002255 cell
membrane
protein binding 319 kDa 4.8 ± 4.6 1.5 ± 0.7 0.3 3.2
12 IGL@ protein IPI00555945 25 kDa 69.0 ± 27.6 21.5 ±
13.4
0.3 3.2
13 Heat shock protein beta-1 IPI00025512 stress response cytoplasm
cytoskeleton
nucleus
identical protein
binding
23 kDa 7.8 ± 1.1 2.3 ± 1.8 0.3 3.4
14 Glutathione S-transferase P IPI00219757 anti-apoptosis cytoplasm glutathione
transferase activity
23 kDa 34.5 ± 30.4 10.0 ±
9.2
0.3 3.5
15 S100-A2 IPI00019869 endothelial cell
migration
calcium ion
binding
11 kDa 4.5 ± 0.7 1.3 ± 0.4 0.3 3.6
16 Glutathione transferase omega-1 IPI00019755 cytoplasm glutathione
transferase activity
28 kDa 4.0 ± 1.4 1.0 ± 0.7 0.3 4.0
17 Carbonyl reductase [NADPH] 1 IPI00295386 oxidation reduction cytoplasm oxidoreductase 30 kDa 7.8 ± 3.2 1.3 ± 1.1 0.2 6.2
18 CRISP3 cDNA FLJ75207 IPI00004798 extracellular
region
29 kDa 7.0 ± 7.8 1.0 ± 1.4 0.1 7.0
19 Isoform 1 of Serpin B3 IPI00022204 cytoplasm serine protease
inhibitor
45 kDa 4.5 ± 2.1 0.5 ± 0.0 0.1 9.0
20 Aldo-keto reductase family 1 member B10 IPI00105407 oxidation reduction cytoplasm oxidoreductase 36 kDa 4.8 ± 3.2 0.3 ± 0.4 0.1 19.0
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1MP patients. For the further analysis of bacterial pro-
teins, more classified samples and an efficient isolation
method for bacterial proteins are needed.
Genomic and proteomic studies were performed to
discover biologically-regulated signatures in periodontitis
patients. Recently, the profiling of periodontitis-related
molecules was reported. In 2008, a transcriptome analy-
sis of gingival tissue was performed using 54,675 probe
sets in 64 healthy sites and 183 inflamed sites [5]. The
study reported 12,744 differentially expressed probe sets,
which classified 16 groups related to functions such as
apoptosis, the antimicrobial humoral response, and anti-
gen presentation, as determined by gene ontology analy-
sis. There were also proteomic studies on GCF itself.
The GCF of a healthy donor was collected using sterile
blotting paper cones, and serum albumin, a-defensins
1-4, cystatin A, statherin, and basic PB salivary peptide
were detected in the acidic extracts of GCF using
HPLC-ESI-MS [25]. In another study, GCF samples col-
lected from inflamed periodontal sites using sterile glass
microcapillary tubes were analyzed using MALDI-TOF/
TOF MS and LC-ESI-MS/MS. Among the 66 proteins
identified in human GCF, 43 proteins, which included
actin, profilin, cofilin, and gelsolin, were first reported in
GCF [26]. In a recent study, 40 GCF samples were col-
lected from 5 healthy individuals and 5 aggressive peri-
odontitis patients using sterile periopaper strips and
analyzed by LC-MS, a label-free mass spectrometry.
Among the 154 identified proteins, annexin-1 was
expressed at a 5-fold higher level in healthy individuals,
and L-plastin (plastin-2/LCP1) was detected only in per-
iodontitis patients [27].
In accordance with a previous report, myeloperoxi-
d a s e ,m y o s i n9 ,a n n e x i nA 3 ,p r o f i l i n - 1 ,L - p l a s t i n
Figure 2 Verification of azurocidin expression in the GCF samples. Azurocidin expression was confirmed in the GCF samples used for
proteomic analysis by western blot (A) and the ELISA assay (B). (C) Azurocidin expression was further confirmed by ELISA in 156 individual GCF
samples: 31 healthy individuals (N), 36 chronic gingivitis (GV), 59 moderate periodontitis (MP), and 30 severe chronic periodontitis (SP) patients
(Additional files 2). All subjects were non-smokers and had no other disease indications or other conditions, e.g., diabetes, arteriosclerosis,
hepatitis, AIDS, hypertension or pregnancy. Black diamond, Individuals; -, Average; —, Cutoff. After the cutoff was set at 50 pg/ml, the sensitivity
and specificity of azurocidin for the periodontitis patients were calculated (Table 4).
Table 4 Comparison of studies that have reported on the identification of the GCF proteome
N (n = 31) GV (n = 36) MP (n = 59) SP (n = 30)
Average (pg/ml) 40.8 136.6 118.3 85.3
Specificity (%) 74.2 - - -
Sensitivity (%) - 66.7 76.3 60.0
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Page 8 of 11(plastin-2/LCP1), S100A8, and S100A9 were detected at
higher levels in chronic periodontitis patients compared
to healthy individuals. The expression of cystatin-B was
decreased in periodontitis patients compared to healthy
controls [27]. Although cornifin-A and S100-P were
identified by small peptide hits, S100-P was upregulated
and cornifin-A was downregulated in the GCF of peri-
odontitis patients compared to healthy individuals, in
both our study and the previous study [27]. Additionally,
we identified three proteins, azurocidin, neutrophil elas-
tase 2 (ELA2), and myeloperoxidase (proteinase 3), that
are known to be found in azurophil granules, the specia-
lized lysosomes of neutrophils. These three proteins
were consistently detected at higher levels in the GCF of
chronic periodontitis patients (Table 2). Azurocidin,
ELA2, and myeloperoxidase are located in a cluster on
chromosome 19 and are constituents of azurophil gran-
ules during neutrophil differentiation [28].
Azurocidin is also known as heparin-binding protein
(HBP) or cationic antimicrobial protein of 37 kDa
(CAP37) [29]. Azurocidin, a member of the serine pro-
teases, is homologous to cathepsin G, elastase, and
Figure 3 Azurocidin expression in gingival tissues by western blot. Protein expression levels of azurocidin were confirmed in gingival tissue
using western blotting. Gingival tissues were sorted by the stage of chronic gingivitis and periodontitis. The gingival tissues used for the
confirmation of azurocidin expression were from 2 healthy individuals (N) and 3 chronic gingivitis (GV), 3 moderate periodontitis (MP), and 3
severe chronic periodontitis (SP) patients. The detected sizes of azurocidin were approximately 27 kDa. After loading 5 μg of protein, anti-human
azurocidin and anti-b-actin antibodies were used for detection. Overall, azurocidin expression was higher in periodontitis patients as compared
to healthy individuals.
Figure 4 Inhibition of osteoclast differentiation by azurocidin. Mouse bone marrow monocytes (BMM) isolated from BALB/c mice were
incubated in media containing RANKL (20 ng/ml) plus M-CSF (20 ng/ml) with the given concentration of azurocidin for 3 days. Osteoclast
differentiation was evaluated by TRAP staining. The fused osteoclast cells revealed by TRAP staining were decreased with increasing dosages of
azurocidin.
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Page 9 of 11proteinase 3 (PR-3; myeloblastin) but is known to lack
proteolytic activity [30,31]. Azurocidin was first identi-
fied as a cationic antimicrobial protein (CAP) in human
polymorphonuclear granulocyte (PMN) granules and
exhibits an antimicrobial activity against Gram-negative
bacteria (Salmonella typhimurium), Gram-positive bac-
teria (Staphylococcus aureus) and fungi (Candida albi-
cans) [29,32,33]. Recombinant azurocidin induces the
release of interleukin-6 and tumor necrosis factor-alpha
(TNF-a) from human monocytes upon lipopolysacchar-
ide (LPS) stimulation [34]. During the extravasation cas-
cade of PMN, azurocidin serves as an alarmin and is
released from infection sites to activate inflammatory
cells [23].
In this study and for the first time, we identified azur-
ocidin in GCF as a periodontitis biomarker. Through
mass spectrometry, we determined that the azurocidin
level is highly elevated in the GCF of chronic periodon-
titis patients (Table 2), and we also confirmed these
results in different stages of periodontitis using an
ELISA analysis (Figure 2C). Azurocidin levels are higher
in GV and MP, compared to SP, and might serve as a
promising biomarker for the development of the early
diagnosis of periodontitis.
Periodontitis is a disease that affects the immune sys-
tem and results in alveolar bone loss at its severe stages.
Evidence has accumulated on the crosstalk between the
immune and bone systems [35-38]. Immune response
cytokines, such as TNF-a, interleukin, and interferon,
affect the differentiation and activity of osteoclasts and
bone resorption. In addition, immune cells produce and
release key factors (RANKL and M-CSF) for osteoclasto-
genesis. In regards to this aspect, we have shown the
inhibitory effect of azurocidin on osteoclastogenesis from
BMM (Figure 4). Thus, it is suggested that azurocidin
elevation during gingivitis may have a protective effect on
alveolar bone during the early stages of periodontitis. In
SP patients, however, the reduced level of azurocidin may
lose its protective effect, which may lead to increased
alveolar bone loss during later stages of periodontitis.
Conclusions
Our GCF proteomic study suggests that GCF collection
using a gel loading tip followed by LC-MS/MS analysis
is a useful method for analyses of periodontitis GCF bio-
markers. Our data have revealed that azurocidin may be
a potential biomarker candidate for the early detection
of periodontal destruction by the inflammation in gingi-
vitis and some chronic periodontitis based on the mass
spectrometry, western blot and ELISA data using GCF
samples. In addition, we have shown that azurocidin
may have an inhibitory role on osteoclast differentiation,
which suggests that azurocidin may decrease alveolar
bone loss during periodontitis.
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